Approval · Notice of Compliance 2198 · 2001
TIAZAC: Notice of Compliance 2198
Issued November 13, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2198
- Date
- November 13, 2001
- Company
- Biovail Pharmaceuticals, Division Of Biovail CorporationMississauga, ON, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Antihypertensive/antianginal agent
Products in this notice
Medicinal ingredients
- DILTIAZEM HCL 120 MG per CAP
- DILTIAZEM HCL 180 MG per CAP
- DILTIAZEM HCL 240 MG per CAP
- DILTIAZEM HCL 300 MG per CAP
- DILTIAZEM HCL 360 MG per CAP